MMV will contribute intellectual property to the Pool for Open Innovation Against Neglected Tropical Diseases.
The Pool for Open Innovation Against Neglected Tropical Diseases was established in February 2009 by GSK (GlaxoSmithKline) and Alnylam Pharmaceuticals and has since been joined by MIT (Massachusetts Institute of Technology). It seeks to stimulate innovative and efficient drug discovery and development by providing public access to intellectual property (IP) and scientific know-how for neglected tropical disease research. The Pool is administered by BIO Ventures for Global Health (BVGH).
As contributor to the Pool, MMV will make available its IP, technology and expertise in the research and development (R&D) of antimalarial drugs to researchers developing medicines for neglected diseases.
“MMV is proud to be a contributor to the Pool for Open Innovation Against Neglected Tropical Diseases and to join a group of like-minded organizations dedicated to researching new health tools for neglected diseases. Our contribution to the Pool is in line with MMV’s commitment to allow any patents and technologies resulting from our R&D work, developing new, effective and affordable medicines for malaria, to be used for public good. Researchers will now have access to MMV’s know-how, free of charge, to discover and develop medicines for neglected diseases that are an enormous burden on the poorer patients in the developing world,” said Prof. Patrick Nef, EVP Business Development of MMV.